Clinical trials: Metastatic Colorectal Carcinoma
Colon Cancer Liver Metastasis
Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer
This is a multicentre, open labeled, single arm study to determine effectiveness and safety of chemoembolization with Irinotecan-Eluting Bead(DEBIRI) in the treatment of unresectable liver metastases in patients with colorectal…
- Trial name
- DEBIRI-CRLM (NCT03175016)
- Testing
- TACE, Irinotecan, eluting-bead
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Recurrent Colon Cancer, Recurrent Rectal Cancer
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT01294826
- Testing
- AUY922, Cetuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Swedish Medical Center
Colorectal Neoplasms
Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer
This study will evaluate the safety and tolerability of a personalized live, attenuated, double-deleted Listeria monocytogenes (pLADD) treatment in adults with metastatic colorectal cancer.
- Trial name
- NCT03189030
- Testing
- pLADD
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Aduro Biotech, Inc.
Metastatic Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
The purpose of this study is to evaluate the efficacy and safety of selinexor alone or with pembrolizumab in participants with advanced or metastatic colorectal cancer (CRC).
- Trial name
- NCT04854434
- Testing
- Selinexor, Pembrolizumab, Trifluridine
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Karyopharm Therapeutics Inc
Colon Cancer, Immunotherapy
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. To investigate the effective biomarker of anlotinib combined with tiralizumab
- Trial name
- NCT06573424
- Testing
- Tislelizumab+anlotinib, anlotinib
- Where
- China
- Volunteers
- 124 people
- Sponsor
- fan li
Metastatic Carcinoma, Stage IV Colorectal Cancer
Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
This research trial studies the gut microbiome in fecal samples from patients with cancer that has spread to other parts of the body who are undergoing chemotherapy or immunotherapy.
- Conditions
- Metastatic Carcinoma, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT02960282
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Southern California
Colorectal Neoplasms, Diarrhea
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
The study will combine a new investigational drug with standard anti-cancer drugs for the treatment of advanced colorectal cancer.
- Trial name
- NCT00040391
- Testing
- Investigational drug, Irinotecan, 5-fluorouracil
- Where
- 28 sites in United States
- Sponsor
- Celgene Corporation
Colorectal Cancer
Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182715
- Testing
- cetuximab, capecitabine, fluorouracil
- Where
- 82 sites in Ireland, United Kingdom
- Volunteers
- 2,421 people
- Sponsor
- Velindre NHS Trust
Mesothelioma, Bladder Cancer
Safety Study of MGD009 in B7-H3-expressing Tumors
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely.
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02628535
- Testing
- MGD009
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- MacroGenics
Colorectal Neoplasms
Stivarga Real Life Evidence in Hungary
The study aims to evaluate use of regorafenib in clinical practice in Hungary. The study should provide information about clinical characteristics of Hungarian regorafenib patients as well as information about safety and efficacy…
- Trial name
- NCT02656524
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Hungary
- Volunteers
- 400 people
- Sponsor
- Bayer
Metastatic Uveal Melanoma, Cutaneous Melanoma
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including…
- Conditions
- Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
- Trial name
- NCT03947385
- Testing
- IDE196, Binimetinib, Crizotinib
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 336 people
- Sponsor
- IDEAYA Biosciences
Metastatic Colorectal Cancer
Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.
Iron deficiency has a high prevalence in colorectal cancer patients ranging at ca. 60%. About 70% of these patients suffer from iron deficiency anemia (IDA) which adds both physical and cognitive impediments to an already…
- Trial name
- NCT02469480
- Testing
- FerInject, Ferro sanol
- Where
- 18 sites in Germany
- Volunteers
- 64 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Liver Neoplasms, Neoplasm Metastasis
Study of NS-9 in Patients With Liver Metastases
This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor.
- Conditions
- Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences
- Trial name
- NCT00094003
- Testing
- NS-9 [Poly I: Poly C]
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NS Pharma, Inc.
Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer
Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease
Non-commercial, prospective, randomized, multicenter, national, phase II, open-label comparative clinical trial. The patients will be randomized in a 1: 1 ratio in two arms: Control arm.
- Trial name
- LIVERPEARL (NCT04595266)
- Testing
- FOLFOX regimen, Anti-EGFR or Bevacizumab, LIVERPEARLS-Irinotecan
- Where
- 8 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer
A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new drug, OMP-21M18, when given in combination with FOLFIRI, a standard drug treatment for advanced colorectal cancer.
- Trial name
- NCT01189942
- Testing
- OMP-21M18
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 18 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Colorectal Cancer Metastatic
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
The objective of this clinical trial is to evaluate the efficacy and safety of cetuximab combined with PD-1 inhibitor and irinotecan in negative ultraselection RAS/BRAF wild-type refractory right-sided metastatic colorectal…
- Trial name
- NCT06547203
- Testing
- Cetuximab, Toripalimab, Irinotecan
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib…
- Trial name
- NCT07035886
- Testing
- No intervention
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Takeda
Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
The goal of this phase II randomized controlled clinical trial is to evaluate whether adding lubiprostone to standard postoperative maintenance therapy can delay disease progression and recurrence in adult patients with…
- Conditions
- Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer, Peritoneal Metastasis, Colorectal Cancer (CRC)
- Trial name
- NCT07405736
- Testing
- maintenance therapy plus lubiprostone, maintenance therapy
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer With Liver Metastatic
YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases
This study was a prospective, single-center, open-label, single-arm, multi-dose ascending phase Ⅰ clinical trial. The investigators constructed a TM10-LNP mRNA preparation encoding CTLA-4 antibody and TGF-β trap bifunction…
- Trial name
- NCT07610707
- Testing
- YMN-A02 100μg, YMN-A02 250μg, YMN-A02 500μg
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Metastatic Colorectal Cancer
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
This include two parts, part 1 is a dose optimizing study and part 2 is a randomized, controlled study.
- Trial name
- NCT05130021
- Testing
- MAX-40279-01, regorafenib
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Maxinovel Pty., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.